featured
Lenvatinib Plus Pembrolizumab vs Sunitinib as First-Line Treatment for Advanced RCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
Lancet Oncol 2023 Mar 01;24(3)228-238, TK Choueiri, M Eto, R Motzer, U De Giorgi, T Buchler, NS Basappa, MJ Méndez-Vidal, S Tjulandin, S Hoon Park, B Melichar, T Hutson, C Alemany, B McGregor, T Powles, V Grünwald, B Alekseev, SY Rha, E Kopyltsov, A Kapoor, T Alonso Gordoa, JC Goh, M Staehler, JR Merchan, R Xie, RF Perini, K Mody, J McKenzie, CG PortaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.